 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
50 News |  |
- tamoxifen / Generic mfg.
Multi omics reveals silencing of Argininosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance invasive lobular carcinoma (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1115;
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2409;
In addition, farudodstat did not induce catagen, nor did it cause cytotoxicity, affect keratinocyte proliferation, or IP marker expression in healthy HFs. These preliminary data demonstrate anti-CD3/CD28 treatment induced features of AA in an ex vivo disease model and provide promising evidence for the therapeutic potential of farudodstat in patients suffering from AA.
- | farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Phase classification, Trial completion date, Trial primary completion date: FAST-AA: Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants (clinicaltrials.gov) - Dec 18, 2023
P2, N=60, Recruiting, Sponsor: ASLAN Pharmaceuticals
These preliminary data demonstrate anti-CD3/CD28 treatment induced features of AA in an ex vivo disease model and provide promising evidence for the therapeutic potential of farudodstat in patients suffering from AA. Phase classification: P2a --> P2 | Trial completion date: Apr 2024 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Sep 2024
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse () - Nov 6, 2023 - Abstract #ISDS2023ISDS_255;
Preliminary results show that anti-CD3/CD28 treatment in this ex vivo model can successfully stimulate T-cell proliferation, which subsequently induces key features of AA, including stimulation of MHC I and II expression in the bulb. Additionally, our data suggest that farudodstat might protect HFs from IP collapse and offer a novel therapeutic approach for AA.
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse (e-Poster Hall) - Sep 27, 2023 - Abstract #EADV2023EADV_4645;
Our preliminary results show that anti-CD3/CD28 treatment in this ex vivo model can successfully stimulate T cell proliferation, which subsequently induces key features of AA including upregulation of MHC I and II as markers of IP collapse. Additionally, our data suggest that farudodstat might protect from IP collapse and offer a novel therapeutic approach for AA, which deserves further pre-clinical investigation.
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse (M1+2) - Aug 30, 2023 - Abstract #EADV2023EADV_4498;
Our preliminary results show that anti-CD3/CD28 treatment in this ex vivo model can successfully stimulate T cell proliferation, which subsequently induces key features of AA including upregulation of MHC I and II as markers of IP collapse. Additionally, our data suggest that farudodstat might protect from IP collapse and offer a novel therapeutic approach for AA, which deserves further pre-clinical investigation.
- | farudodstat (ASLAN003) / Almirall, ASLAN Pharma
New P2a trial: FAST-AA: Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants (clinicaltrials.gov) - May 18, 2023
P2a, N=60, Recruiting, Sponsor: ASLAN Pharmaceuticals
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment () - Apr 13, 2023 - Abstract #ISID2023ISID_2288;
Additionally, our data suggest that farudodstat might protect from IP collapse and offer a novel therapeutic approach for AA, which deserves further pre-clinical investigation. CONTROL ID: 3918078.
- | farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Journal: Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold. (Pubmed Central) - Nov 2, 2022
Furthermore, 7d exhibited favorable safety profiles in mice and displayed effective antitumor activities with tumor growth inhibition (TGI) rates of 58.3% and 42.1% at an oral dosage of 30 mg/kg in Raji and HCT116 cells xenograft models, respectively. Taken together, these findings provide a promising hDHODH inhibitor 7d with potential activities against some tumors.
- | farudodstat (ASLAN003) / Almirall, ASLAN Pharma, ONC201 / Chimerix
Preclinical, Journal: IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro. (Pubmed Central) - Oct 12, 2022
ONC201 is a well-known caseinolytic protease (ClpP)activator with established benefits against multiple tumors, including colorectal cancer (CRC)...Our findings substantiate that IMP075 exerts excellent antitumor effects against CRC by activating ClpP-mediated impairment of mitochondrial function. Due to its superior properties, IMP075 appears to be have huge prospects for application.
- | Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Inhibitors of dihydroorotate dehydrogenase cooperate with Molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication. (Pubmed Central) - May 3, 2022
DHODH inhibitors increased the antiviral efficiency of Molnupiravir not only in organoids of human lung, but also in Syrian Gold hamsters and in K18-hACE2 mice. Combining Molnupiravir with DHODH inhibitors may thus improve available therapy options for COVID-19.
- | farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Trial completion, Enrollment change: A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 2, 2021
P2a, N=24, Completed, Sponsor: Aslan Pharmaceuticals
Combining Molnupiravir with DHODH inhibitors may thus improve available therapy options for COVID-19. Recruiting --> Completed | N=56 --> 24
- | ASLAN003 / Almirall, ASLAN
Journal: ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. (Pubmed Central) - Apr 28, 2021
Our results, therefore, suggest that ASLAN003 is an agent targeting dihydroorotate dehydrogenase with potential in the treatment of acute myeloid leukemia. ASLAN003 is currently being evaluated in phase 2a clinical trial in acute myeloid leukemia patients.
- | ASLAN003 / Almirall, ASLAN
Journal: ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. (Pubmed Central) - Nov 9, 2019
Our results, therefore, suggest that ASLAN003 is an agent targeting dihydroorotate dehydrogenase with potential in the treatment of acute myeloid leukemia. ASLAN003 is currently being evaluated in phase 2a clinical trial in acute myeloid leukemia patients.
- | farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Enrollment change, Trial completion date, Trial primary completion date: A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 11, 2019
P2a, N=56, Recruiting, Sponsor: Aslan Pharmaceuticals
ASLAN003 is currently being evaluated in phase 2a clinical trial in acute myeloid leukemia patients. N=38 --> 56 | Trial completion date: Dec 2019 --> Aug 2020 | Trial primary completion date: Jun 2019 --> Apr 2020
- | farudodstat (ASLAN003) / Almirall, ASLAN Pharma
New P2a trial: A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 15, 2018
P2a, N=38, Recruiting, Sponsor: Aslan Pharmaceuticals
- | farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Enrollment change: A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia (clinicaltrials.gov) - May 31, 2018
P2a, N=38, Recruiting, Sponsor: Aslan Pharmaceuticals
N=38 --> 56 | Trial completion date: Dec 2019 --> Aug 2020 | Trial primary completion date: Jun 2019 --> Apr 2020 N=18 --> 38
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Trial completion, Enrollment change: A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects (clinicaltrials.gov) - Jun 23, 2015
P1, N=7, Completed, Sponsor: Aslan Pharmaceuticals
N=18 --> 38 Recruiting --> Completed | N=16 --> 7
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
New P1 trial: A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects (clinicaltrials.gov) - Jan 22, 2015
P1, N=16, Recruiting, Sponsor: Aslan Pharmaceuticals
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
Trial completion: Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003 (clinicaltrials.gov) - Sep 4, 2014
P1, N=61, Completed, Sponsor: Aslan Pharmaceuticals
Recruiting --> Completed | N=16 --> 7 Recruiting --> Completed
- farudodstat (ASLAN003) / Almirall, ASLAN Pharma
New P1 trial: Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003 (clinicaltrials.gov) - Nov 12, 2013
P1, N=64, Recruiting, Sponsor: Aslan Pharmaceuticals